Fc-based cytokines: Prospects for engineering superior therapeutics

BioDrugs

Volumn 22, Issue 1, 2008, Pages 11-26

  Jazayeri, Jalal A ^a   Carroll, Graeme J ^b  

^a MONASH UNIVERSITY   (Australia)

^b FREMANTLE HOSPITAL   (Australia)

Author keywords

Antibody optimisation technologies; Biotechnology; Biotherapies; Cytokines, general

Indexed keywords

ABATACEPT; ADAMTS IMMUNOGLOBULIN FC FRAGMENT; ALBUFUSE; ALTRAKINCEPT; ATR IMMUNOGLOBULIN FC FRAGMENT; BASILIXIMAB; CYTOKINE IMMUNOGLOBULIN FC FRAGMENT; DACLIZUMAB; EPIDERMAL GROWTH FACTOR IMMUNOGLOBULIN FC FRAGMENT; ERYTHROPOIETIN IMMUNOGLOBULIN FC FRAGMENT; ETANERCEPT; FOLLITROPIN IMMUNOGLOBULIN FC FRAGMENT; GLYCOPROTEIN V1 IMMUNOGLOBULIN FC FRAGMENT; HUMAN GROWTH HORMONE RECEPTOR IMMUNOGLOBULIN FC FRAGMENT; INDUCIBLE PROTEIN 10 IMMUNOGLOBULIN FC FRAGMENT; INTERFERON ALPHA IMMUNOGLOBULIN FC FRAGMENT; INTERFERON BETA IMMUNOGLOBULIN FC FRAGMENT; INTERLEUKIN 10 IMMUNOGLOBULIN FC FRAGMENT; INTERLEUKIN 15 IMMUNOGLOBULIN FC FRAGMENT; INTERLEUKIN 18BP IMMUNOGLOBULIN FC FRAGMENT; INTERLEUKIN 4 IMMUNOGLOBULIN FC FRAGMENT; LENERCEPT; MACROGOL; MURINE INTERLEUKIN 17 RECEPTOR IMMUNOGLOBULIN FC FRAGMENT; OMALIZUMAB; OX40 LIGAND IMMUNOGLOBULIN FC FRAGMENT; PLASMID VECTOR; PROTEIN B7.1 IMMUNOGLOBULIN FC FRAGMENT; PROTEIN BP1700 IMMUNOGLOBULIN FC FRAGMENT; RECOMBINANT INTERLEUKIN T3 IMMUNOGLOBULIN FC FRAGMENT; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY IMMUNOGLOBULIN FC FRAGMENT; SYNFUSION; TISSUE INHIBITOR OF METALLOPROTEINASE 3 IMMUNOGLOBULIN FC FRAGMENT; TRANSCEPTOR; TYROSINE KINASE B IMMUNOGLOBULIN FC FRAGMENT; UNCLASSIFIED DRUG; UNINDEXED DRUG; VACCINIA VIRUS COMPLEMENT IMMUNOGLOBULIN FC FRAGMENT;

ANTIBODY ENGINEERING; AUTOIMMUNE DISEASE; BIOENGINEERING; DRUG ACTIVITY; DRUG ANTAGONISM; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG DIFFUSION; DRUG HALF LIFE; DRUG STABILITY; GENE DELIVERY SYSTEM; GENE THERAPY; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOMODULATION; INFLAMMATION; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PURIFICATION; REVIEW;

EID: 38549161562     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-200822010-00002     Document Type: Review

References (113)

1. Song XY, Torphy TJ, Griswold DE, et al. Coming of age: anti-cytokine therapies. Mol Interv 2002 Feb; 2 (1): 36-46
2. Andreakos ET, Foxwell BM, Brennan FM, et al. Cytokines and anti-cytokine biologicals in autoimmunity: present and future. Cytokine Growth Fact Rev 2002; 13 (4-5): 299-313
3. Choy EHS, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 2001 Mar 22; 344 (12): 907-16
4. Vaccaro C, Zhou J, Ober RJ, et al. Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels. Nat Biotechnol 2005 Oct; 23 (10): 1283-8
5. Idusogie EE, Wong PY, Presta LG, et al. Engineered antibodies with increased activity to recruit complement. J Immunol 2001 Feb 15; 166 (4): 2571-5
6. van Meerten T, Claessen MJ, Hagenbeek A, et al. The CD20/alphaCD20 'suicide' system: novel vectors with improved safety and expression profiles and efficient elimination of CD20-transgenic T cells. Gene Ther 2006 May; 13 (9): 789-97
7. van Meerten T, van Rijn RS, Hol S, et al. Complement-induced cell death by rituximab depends on CD20 expression level and acts complementary to antibody-dependent cellular cytotoxicity. Clin Cancer Res 2006 Jul 1; 12 (13): 4027-35
8. Hamilton RG. Human IgG subclass measurements in the clinical laboratory. Clin Chem 1987 Oct; 33 (10): 1707-25
9. Daeron M. Fc receptor biology. Annu Rev Immunol 1997; 15: 203-34
10. Jefferis R, Lund J. Interaction sites on human IgG-Fc for Fc[gamma]R: current models. Immunol Lett 2002; 82 (1-2): 57-65
11. Shields RL, Namenuk AK, Hong K, et al. High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. J Biol Chem 2001; 276 (9): 6591-604
12. Kraneveld AD, Kool M, van Houwelingen AH, et al. Elicitation of allergic asthma by immunoglobulin free light chains. Proc Natl Acad Sci U S A 2005 Feb 1; 102 (5): 1578-83
13. Fridman WH. Fc receptors and immunoglobulin binding factors. FASEB J 1991 Sep; 5 (12): 2684-90
14. Gillies SD, Lan Y, Lo KM, et al. Improving the efficacy of antibody-interleukin 2 fusion proteins by reducing their interaction with Fc receptors. Cancer Res 1999 May 1; 59 (9): 2159-66
15. Gillies SD, Lo KM, Burger C, et al. Improved circulating half-life and efficacy of an antibody-interleukin 2 immunocytokine based on reduced intracellular proteolysis. Clin Cancer Res 2002 Jan; 8 (1): 210-6
16. Dall'Acqua WF, Woods RM, Ward ES, et al. Increasing the affinity of a human IgG1 for the neonatal Fc receptor: biological consequences. J Immunol 2002 Nov 1; 169 (9): 5171-80
17. Hinton PR, Xiong JM, Johlfs MG, et al. An engineered human IgG1 antibody with longer serum half-life. J Immunol 2006 Jan 1; 176 (1): 346-56
18. Guan KL, Dixon JE. Eukaryotic proteins expressed in Escherichia coli: an improved thrombin cleavage and purification procedure of fusion proteins with glutathione S-transferase. Anal Biochem 1991 Feb 1; 192 (2): 262-7
19. Lo KM, Sudo Y, Chen J, et al. High level expression and secretion of Fc-X fusion proteins in mammalian cells. Protein Eng 1998 Jun; 11 (6): 495-500
20. Liu J, Wei D, Qian F, et al. pPIC9-Fc: a vector system for the production of single-chain Fv-Fc fusions in Pichia pastoris as detection reagents in vitro. J Biochem (Tokyo) 2003 Dec; 134 (6): 911-7
21. Simmons LC. Expression of full-length immunoglobulins in Escherichia coli: rapid and efficient production of aglycosylated antibodies. J Immunol Methods 2002; 263: 133-47
22. Bessette PH, Aslund F, Beckwith J, et al. Efficient folding of proteins with multiple disulfide bonds in the Escherichia coli cytoplasm. Proc Natl Acad Sci U S A 1999 Nov 23; 96 (24): 13703-8
23. Wu SC, Wong SL. Engineering of a Bacillus subtilis strain with adjustable levels of intracellular biotin for secretory production of functional streptavidin. Appl Environ Microbiol 2002 Mar; 68 (3): 1102-8
24. Binnie C, Jenish D, Cossar D, et al. Expression and characterization of soluble human erythropoietin receptor made in Streptomyces lividans 66. Protein Expr Purif 1997 Dec; 11 (3): 271-8
25. Joosten V, Lokman C, Van Den Hondel CA, et al. The production of antibody fragments and antibody fusion proteins by yeasts and filamentous fungi. Microb Cell Fact 2003 Jan 30; 2 (1): 1
26. Ghose S, Hubbard B, Cramer SM. Binding capacity differences for antibodies and Fc-fusion proteins on protein A chromatographic materials. Biotechnol Bioeng 2006 Jul 1; 96 (4): 768-79
27. Nagaoka M, Akaike T. Single amino acid substitution in the mouse IgG1 Fc region induces drastic enhancement of the affinity to protein A. Protein Eng 2003; 16: 243-5
28. Jazayeri JA, De Weerd N, Raye W, et al. Generation of mutant leukaemia inhibitory factor (LIF)-IgG heavy chain fusion proteins as bivalent antagonists of LIF. J Immunol Methods 2007 May 31; 323 (1): 1-10
29. Feldmann M. Development of anti-TNF therapy for rheumatoid arthritis. Nat Rev Immunol 2002 May; 2 (5): 364-71
30. Binley JM, Ngo-Abdalla S, Moore P, et al. Inhibition of HIV Env binding to cellular receptors by monoclonal antibody 2G12 as probed by Fc-tagged gp120. Retrovirology 2006; 3: 39
31. Meier W, Gill A, Rogge M, et al. Immunomodulation by LFA3TIP, an LFA-3/IgG1 fusion protein: cell line dependent glycosylation effects on pharmacokinetics and pharmacodynamic markers. Ther Immunol 1995 Jun; 2 (3): 159-71
32. Davis PM, Nadler SG, Rouleau KA, et al. Abatacept (CTLA4-Ig) modulates human T-cell proliferation and cytokine production but does not affect lipopolysaccharide-induced tumor necrosis factor alpha production by monocytes. Arth Res Ther 2005; 7 Suppl. 1: 21
33. Hendeles L, Asmus M, Chesrown S. Evaluation of cytokine modulators for asthma. Paediatr Respir Rev 2004; 5 Suppl. A: S107-12
34. Ramirez CB, Marino IR. The role of basiliximab induction therapy in organ transplantation. Expert Opin Biol Ther 2007 Jan; 7 (1): 137-48
35. Forrest K, Logan B, Strange J, et al. Daclizumab therapy in kidney transplantation-different mechanisms of action in- versus ex-vivo? Transpl Immunol 2005 Mar; 14 (1): 43-7
36. Wurzburg BA, Garman SC, Jardetzky TS. Structure of the human IgE-Fc C[var epsilon]3-C[var epsilon]4rReveals conformational flexibility in the antibody effector domains. Immunity 2000; 13 (3): 375-85
37. Qin W, Feng J, Li Y, et al. Fusion protein of CDR mimetic peptide with Fc inhibit TNF-alpha induced cytotoxicity. Mol Immunol 2006 Feb; 43 (6): 660-6
38. Kim-Schulze S, Scotto L, Vlad G, et al. Recombinant Ig-like transcript 3-Fc modulates T cell responses via induction of Th anergy and differentiation of CD8+ T suppressor cells. J Immunol 2006 Mar 1; 176 (5): 2790-8
39. Kim YS, Maslinski W, Zheng XX, et al. Targeting the IL-15 receptor with an antagonist IL-15 mutant/Fc gamma2a protein blocks delayed-type hypersensitivity. J Immunol 1998 Jun 15; 160 (12): 5742-8
40. Zheng XX, Gao W, Donskoy E, et al. An antagonist mutant IL-15/Fc promotes transplant tolerance. Transplantation 2006 Jan 15; 81 (1): 109-16
41. Nickerson P, Zheng XX, Steiger J, et al. Prolonged islet allograft acceptance in the absence of interleukin 4 expression. Transpl Immunol 1996 Mar; 4 (1): 81-5
42. Zheng XX, Steele AW, Hancock WW, et al. A noncytolytic IL-10/Fc fusion protein prevents diabetes, blocks autoimmunity, and promotes suppressor phenomena in NOD mice. J Immunol 1997 May 1; 158 (9): 4507-13
43. Bush KA, Farmer KM, Walker JS, et al. Reduction of joint inflammation and bone erosion in rat adjuvant arthritis by treatment with interleukin-17 receptor IgG1 Fc fusion protein. Arthritis Rheum 2002 Mar; 46 (3): 802-5
44. Ono K, Kamihira M, Kuga Y, et al. Production of anti-prion scFv-Fc fusion proteins by recombinant animal cells. J Biosci Bioeng 2003; 95 (3): 231-8
45. Sivakumar PV, Westrich GM, Kanaly S, et al. Interleukin 18 is a primary mediator of the inflammation associated with dextran sulphate sodium induced colitis: blocking interleukin 18 attenuates intestinal damage. Gut 2002 Jun; 50 (6): 812-20
46. Vu JR, Fouts T, Bobb K, et al. An immunoglobulin fusion protein based on the gp120-CD4 receptor complex potently inhibits human immunodeficiency virus type 1 in vitro. AIDS Res Hum Retroviruses 2006 Jun; 22 (6): 477-90
47. Liu A, Hu P, Khawli LA, et al. Combination B7-Fc fusion protein treatment and Treg cell depletion therapy. Clin Cancer Res 2005 Dec 1; 11 (23): 8492-502
48. Way JC, Lauder S, Brunkhorst B, et al. Improvement of Fc-erythropoietin structure and pharmacokinetics by modification at a disulfide bond. Protein Eng Des Sel 2005 Mar; 18 (3): 111-8
49. Gurbaxani BM, Morrison SL. Development of new models for the analysis of Fc-FcRn interactions. Mol Immunol 2006 Mar; 43 (9): 1379-89
50. Low SC, Nunes SL, Bitonti AJ, et al. Oral and pulmonary delivery of FSH-Fc fusion proteins via neonatal Fc receptor-mediated transcytosis. Hum Reprod 2005 Jul; 20 (7): 1805-13
51. Zubairi S, Sanos SL, Hill S, et al. Immunotherapy with OX40L-Fc or anti-CTLA-4 enhances local tissue responses and killing of Leishmania donovani. Eur J Immunol 2004 May; 34 (5): 1433-40
52. Croll SD, Chesnutt CR, Rudge JS, et al. Co-infusion with a TrkB-Fc receptor body carrier enhances BDNF distribution in the adult rat brain. Exp Neurol 1998 Jul; 152 (1): 20-33
53. Sugiura T. Baculoviral expression of correctly processed ADAMTS proteins fused with the human IgG-Fc region. J Biotechnol 2003 Feb 13; 100 (3): 193-201
54. Dumont JA, Low SC, Peters RT, et al. Monomeric Fc fusions: impact on pharmacokinetic and biological activity of protein therapeutics. BioDrugs 2006; 20 (3): 151-60
55. Jazayeri JA, DeWeerd N, Ryan W, et al. Evaluation of leukaemia inhibitory factor receptor antagonists as candidate therapeutics for inflammatory arthritis. J Interferon Cytokine Res 2007; 27 (4): 281-9
56. Ogiwara K, Nagaoka M, Cho CS, et al. Construction of a novel extracellular matrix using a new genetically engineered epidermal growth factor fused to IgG-Fc. Biotechnol Lett 2005 Oct; 27 (20): 1633-7
57. Massberg S, Konrad I, Bultmann A, et al. Soluble glycoprotein VI dimer inhibits platelet adhesion and aggregation to the injured vessel wall in vivo. FASEB J 2004 Feb; 18 (2): 397-9
58. Gao LH, Hu XW, Chen W, et al. Expression of ATR-Fc fusion protein in CHO cells [Chinese]. Sheng Wu Gong Cheng Xue Bao 2005 Sep; 21 (5): 826-31
59. Booth V, Keizer DW, Kamphuis MB, et al. The CXCR3 binding chemokine IP-10/CXCL10: structure and receptor interactions. Biochemistry 2002 Aug 20; 41 (33): 10418-25
60. Mazanet MM, Hughes CC. B7-H1 is expressed by human endothelial cells and suppresses T cell cytokine synthesis. J Immunol 2002 Oct 1; 169 (7): 3581-8
61. Kong QL, Guan YZ, Jing XF, et al. BPI700-Fc gamma1 (700) chimeric gene expression and its protective effect in a mice model of the lethal E. coli infection. Chin Med J (Engl) 2006 Mar 20; 119 (6): 474-81
62. Lee CH, Woo JH, Cho KK, et al. Expression and characterization of human growth hormone-Fc fusion proteins for transcytosis induction. Biotechnol Appl Biochem 2007 Apr; 46 (Pt 4): 211-7
63. Sanchez-Fueyo A, Tian J, Picarella D, et al. Tim-3 inhibits T helper type 1-mediated auto- and alloimmune responses and promotes immunological tolerance. Nat Immunol 2003 Nov; 4 (11): 1093-101
64. Vugmeyster Y, Seshasayee D, Chang W, et al. A soluble BAFF antagonist, BR3-Fc, decreases peripheral blood B cells and lymphoid tissue marginal zone and follicular B cells in cynomolgus monkeys. Am J Pathol 2006 Feb; 168 (2): 476-89
65. Gazit R, Rechnitzer H, Achdout H, et al. Recognition of Mycoplasma hyorhinis by CD99-Fc molecule. Eur J Immunol 2004 Jul; 34 (7): 2032-40
66. Sandalon Z, Bruckheimer EM, Lustig KH, et al. Secretion of a TNFR: Fc fusion protein following pulmonary administration of pseudotyped adeno-associated virus vectors. J Virol 2004 Nov; 78 (22): 12355-65
67. Zheng XX, Steele AW, Hancock WW, et al. IL-2 receptor-targeted cytolytic IL-2/Fc fusion protein treatment blocks diabetogenic autoimmunity in nonobese diabetic mice. J Immunol 1999 Oct 1; 163 (7): 4041-8
68. Ma Q, DeMarte L, Wang Y, et al. Carcinoembryonic antigen-immunoglobulin Fc fusion protein (CEA-Fc) for identification and activation of anti-CEA immunoglobulin-T-cell receptor-modified T cells, representative of a new class of Ig fusion proteins. Cancer Gene Ther 2004 Apr; 11 (4): 297-306
69. Zocher M, Baeuerle PA, Dreier T, et al. Specific depletion of autoreactive B lymphocytes by a recombinant fusion protein in vitro and in vivo. Int Immunol 2003 Jul; 15 (7): 789-96
70. Nitschke L, Floyd H, Ferguson DJ, et al. Identification of CD22 ligands on bone marrow sinusoidal endothelium implicated in CD22-dependent homing of recirculating B cells. J Exp Med 1999 May 3; 189 (9): 1513-8
71. Silva-Santos B, Pennington DJ, Hayday AC. Lymphotoxin-mediated regulation of gamma delta cell differentiation by alpha beta T cell progenitors. Science 2005 Feb 11; 307 (5711): 925-8
72. Kumar M, Hunag Y, Glinka Y, et al. Gene therapy of diabetes using a novel GLP-1//IgG1-Fc fusion construct normalizes glucose levels in db//db mice. Gene Ther 2006; 14 (2): 162-72
73. Economides AN, Carpenter LR, Rudge JS, et al. Cytokine traps: multi-component, high-affinity blockers of cytokine action. Nat Med 2003 Jan; 9 (1): 47-52
74. Dinarello CA. Anti-cytokine therapeutics and infections. Vaccine 2003; 21 Suppl.: S24-34
75. Adachi O, Nakano A, Sato O, et al. Gene transfer of Fc-fusion cytokine by in vivo electroporation: application to gene therapy for viral myocarditis. Gene Ther 2002 May; 9 (9): 577-83
76. Jiang J, Yamato E, Miyazaki J. Sustained expression of Fc-fusion cytokine following in vivo electroporation and mouse strain differences in expression levels. J Biochem (Tokyo) 2003 Apr; 133 (4): 423-7
77. Bitonti AJ, Dumont JA. Pulmonary administration of therapeutic proteins using an immunoglobulin transport pathway. Adv Drug Deliv Rev 2006 Oct 31; 58 (9-10): 1106-18
78. Aruffo A, Stamenkovic I, Melnick M, et al. CD44 is the principal cell surface receptor for hyaluronate. Cell 1990 Jun 29; 61 (7): 1303-13
79. Bowen MA, Patel DD, Li X, et al. Cloning, mapping, and characterization of activated leukocyte-cell adhesion molecule (ALCAM), a CD6 ligand. J Exp Med 1995 Jun 1; 181 (6): 2213-20
80. Vinson M, van der Merwe PA, Kelm S, et al. Characterization of the sialic acid-binding site in sialoadhesin by site-directed mutagenesis. J Biol Chem 1996 Apr 19; 271 (16): 9267-72
81. Challita-Eid PM, Penichet ML, Shin SU, et al. A B7.1-antibody fusion protein retains antibody specificity and ability to activate via the T cell costimulatory pathway. J Immunol 1998 Apr 1; 160 (7): 3419-26
82. Greenwald RB. PEG drugs: an overview. J Control Release 2001 Jul 6; 74 (1-3): 159-71
83. Lindsay KL, Trepo C, Heintges T, et al. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 2001; 34 (2): 395-403
84. Davis MW, Feige U, Bendele AM, et al. Treatment of rheumatoid arthritis with PEGylated recombinant human soluble tumour necrosis factor receptor type I: a clinical update. Ann Rheum Dis 2000 Nov; 59 Suppl. 1: i41-3
85. Steinman L. Engineering better cytokines. Nat Biotechnol 2003 Nov; 21 (11): 1293-4
86. Adams G, Vessillier S, Dreja H, et al. Targeting cytokines to inflammation sites. Nat Biotechnol 2003 Nov; 21 (11): 1314-20
87. Chamow SC, Ashkenazi A, editor. Antibody fusion proteins. London: Wiley, 1999
88. Taylor P. Anti-TNF therapy for rheumatoid arthritis and other inflammatory diseases. Mol Biotechnol 2001; 19 (2): 153-68
89. Peppel K, Crawford D, Beutler B. A tumor necrosis factor (TNF) receptor-IgG heavy chain chimeric protein as a bivalent antagonist of TNF activity. J Exp Med 1991; 174 (Dec): 1483-9
90. McKay JRR, Weisman M, et al. A double-blind randomized, six-arm, parallel group, dose finding, double-dummy, multi-center comparison of sTNF p55-IgG (Ro45-2081-lenercept) subcutaneous to reference treatment with oral methotrexate (MTX). Arthritis Rheum 1998; 41: S132
91. TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Neurology 1999 Aug 11; 53 (3): 457-65
92. Holliger P, Winter G. Diabodies: small bispecific antibody fragments. Cancer Immunol Immunother 1997 Nov-Dec; 45 (3-4): 128-30
93. Holliger P, Prospero T, Winter G. 'Diabodies': small bivalent and bispecific antibody fragments. Proc Natl Acad Sci U S A 1993 Jul 15; 90 (14): 6444-8
94. Kim SJ, Park Y, Hong HJ. Antibody engineering for the development of therapeutic antidodes. Mol Cells 2005; 20 (1): 17-29
95. Holliger P, Wing M, Pound JD, et al. Retargeting serum immunoglobulin with bispecific diabodies. Nat Biotechnol 1997 Jul; 15 (7): 632-6
96. Holliger P, Brissinck J, Williams RL, et al. Specific killing of lymphoma cells by cytotoxic T-cells mediated by a bispecific diabody. Protein Eng 1996 Mar; 9 (3): 299-305
97. Shahied LS, Tang Y, Alpaugh RK, et al. Bispecific minibodies targeting HER2/neu and CD16 exhibit improved tumor lysis when placed in a divalent tumor antigen binding format. J Biol Chem 2004 Dec 24; 279 (52): 53907-14
98. Schrama D, Reisfeld RA, Becker JC. Antibody targeted drugs as cancer therapeutics. Nat Rev Drug Discov 2006; 5 (2): 147-59
99. Peng LS, Penichet ML, Dela Cruz JS, et al. Mechanism of antitumor activity of a single-chain interleukin-12 IgG3 antibody fusion protein (mscIL-12. her2.IgG3). J Interferon Cytokine Res 2001 Sep; 21 (9): 709-20
100. Lu D, Zhang H, Koo H, et al. A fully human recombinant IgG-like bispecific antibody to both the epidermal growth factor receptor and the insulin-like growth factor receptor for enhanced antitumor activity. J Biol Chem 2005 May 20; 280 (20): 19665-72
101. Dehal PK, Embleton MJ, Kemshead JT, et al. Targeted cytokine delivery to neuroblastoma. Biochem Soc Trans 2002 Aug; 30 (4): 518-20
102. Lu D, Jimenez X, Zhang H, et al. Fab-scFv fusion protein: an efficient approach to production of bispecific antibody fragments. J Immunol Methods 2002 Sep 15; 267 (2): 213-26
103. Aramwit P, Liu X, Cong X, et al. Bispecific antibodies as emerging pharmaceuticals for tumor immunotherapy. Drugs Future 2005; 20 (10): 1013
104. Kontermann RE. Recombinant bispecific antibodies for cancer therapy. Acta Pharmacol Sin 2005 Jan; 26 (1): 1-9
105. Todorovska A, Roovers RC, Dolezal O, et al. Design and application of diabodies, triabodies and tetrabodies for cancer targeting. J Immunol Methods 2001 Feb 1; 248 (1-2): 47-66
106. Shen WC, Ballou B, Ryser HJ, et al. Targeting, internalization, and cytotoxicity of methotrexate-monoclonal anti-stage-specific embryonic antigen-1 antibody conjugates in cultured F-9 teratocarcinoma cells. Cancer Res 1986; 46: 3912-6
107. Beyersdorf N, Hanke T, Kerkau T, et al. Superagonistic anti-CD28 antibodies: potent activators of regulatory T cells for the therapy of autoimmune diseases. Ann Rheum Dis 2005 Nov 1; 64 Suppl. 4: iv91-5
108. Keane J. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001; 345: 1098-104
109. Chakravarty EF, Michaud K, Wolfe F. Skin cancer, rheumatoid arthritis, and tumor necrosis factor inhibitors. J Rheumatol 2005 Nov; 32 (11): 2130-5
110. Bijay N, Girindra R, Paulette M. TNF-α inhibitor etanercept and hematologic malignancies: report of a case and review of the literature. Am J Hematol 2007; 82 (11): 1022-4
111. Houtman P, Jansen T, Blanken R. Anaphyliactic reaction in a patient with rheumatoid arthritis: a rare side effect of methotrexate with etanercept as a provoking factor? J Clin Rheumatol 2006; 12 (6): 321-2
112. Taylor PC. Biologic therapies for rheumatoid arthritis targeting TNF-α and IL-1. In: Boehncke W-H, Radeke H, editors. Biologics in general medicine. Berlin: Heidelberg, 2007: 111-23
113. Rudick RA, Stuart WH, Calabresi PA, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 2006 Mar 2; 354 (9): 911-23